Meeting
2014 ASCO Annual Meeting
Cancer immunotherapy of patients with the biochemical relapse of the prostate cancer using dendritic cell-based vaccine DCVAC/PCa.
Authors
Radek Spisek
Sotio, Prague, Czech Republic
Radek Spisek , Michal Podrazil , Ladislav Jarolim , Daniela Rozkova , Jitka Fucikova , Anna Fialova , Jirina Bartunkova
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Immunotherapy
Track
Developmental Therapeutics
Sub Track
Vaccines
Clinical Trial Registration Number
2009-017259-91
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3099)
DOI
10.1200/jco.2014.32.15_suppl.3099
Abstract #
3099
Poster Bd #
166
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Salvage radiotherapy (SRT) in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer.
First Author: Markus Grabbert
Poster
2022 ASCO Genitourinary Cancers Symposium
Early initiation of salvage radiotherapy is associated with improved metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.
First Author: Emerson Lee
Poster
2018 Genitourinary Cancers Symposium
Immunotherapy for biochemically recurrent prostate cancer.
First Author: Ravi Amrit Madan
Poster
2017 Genitourinary Cancers Symposium
A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer.
First Author: Neal D. Shore